CaltechAUTHORS
  A Caltech Library Service

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Gini, Beatrice and Heath, James R. (2013) The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas. Clinical Cancer Research, 19 (20). pp. 5722-5732. ISSN 1078-0432. PMCID PMC3815450. https://resolver.caltech.edu/CaltechAUTHORS:20131112-112114444

[img] PDF - Accepted Version
See Usage Policy.

4Mb
[img]
Preview
PDF - Supplemental Material
See Usage Policy.

2500Kb

Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20131112-112114444

Abstract

Purpose: mTOR pathway hyperactivation occurs in approximately 90% of glioblastomas, but the allosteric mTOR inhibitor rapamycin has failed in the clinic. Here, we examine the efficacy of the newly discovered ATP-competitive mTOR kinase inhibitors CC214-1 and CC214-2 in glioblastoma, identifying molecular determinants of response and mechanisms of resistance, and develop a pharmacologic strategy to overcome it. Experimental Design: We conducted in vitro and in vivo studies in glioblastoma cell lines and an intracranial model to: determine the potential efficacy of the recently reported mTOR kinase inhibitors CC214-1 (in vitro use) and CC214-2 (in vivo use) at inhibiting rapamycin-resistant signaling and blocking glioblastoma growth and a novel single-cell technology—DNA Encoded Antibody Libraries—was used to identify mechanisms of resistance. Results: Here, we show that CC214-1 and CC214-2 suppress rapamycin-resistant mTORC1 signaling, block mTORC2 signaling, and significantly inhibit the growth of glioblastomas in vitro and in vivo. EGFRvIII expression and PTEN loss enhance sensitivity to CC214 compounds, consistent with enhanced efficacy in strongly mTOR-activated tumors. Importantly, CC214 compounds potently induce autophagy, preventing tumor cell death. Genetic or pharmacologic inhibition of autophagy greatly sensitizes glioblastoma cells and orthotopic xenografts to CC214-1- and CC214-2–induced cell death. Conclusions: These results identify CC214-1 and CC214-2 as potentially efficacious mTOR kinase inhibitors in glioblastoma, and suggest a strategy for identifying patients most likely to benefit from mTOR inhibition. In addition, this study also shows a central role for autophagy in preventing mTOR-kinase inhibitor-mediated tumor cell death, and suggests a pharmacologic strategy for overcoming it.


Item Type:Article
Related URLs:
URLURL TypeDescription
http://clincancerres.aacrjournals.org/content/19/20/5722PublisherArticle
http://dx.doi.org/10.1158/1078-0432.CCR-13-0527 DOIArticle
http://clincancerres.aacrjournals.org/content/19/20/5722.full.pdf+htmlPublisherSupplemental materials
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815450/PubMed CentralArticle
ORCID:
AuthorORCID
Heath, James R.0000-0001-5356-4385
Additional Information:©2013 American Association for Cancer Research. Received February 27, 2013; revised August 21, 2013; accepted August 22, 2013; published Online First September 12, 2013. Flow cytometry was conducted in the UCLA Jonsson Comprehensive Cancer Center (JCCC) and Center for AIDS Research Flow Cytometry Core Facility that is supported by National Institutes of Health awards CA-16042 and AI-28697, and by the JCCC, the UCLA AIDS Institute, and the David Geffen School of Medicine at UCLA; confocal laser scanning microscopy was conducted at the CNSI Advanced Light Microscopy/Spectroscopy Shared Resource Facility at UCLA. This work is supported by grants from National Institute forNeurological Diseases and Stroke (NS73831), the National Cancer Institute (CA151819), The Ben and Catherine Ivy Foundation, and generous donations from the Ziering Family Foundation in memory of Sigi Ziering. W.K. Cavenee is a Fellow of the National Foundation for Cancer Research. This work is supported, in part, with funding from NIH-NCRR shared resources grant (CJX1-443835-WS-29646) and NSF Major Research Instrumentation grant (CHE-0722519); NIH (NS072838; to D. Guo); and The European Commission (PIOF-GA-2010-271819; to B. Gini). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Funders:
Funding AgencyGrant Number
NIHCA-16042
NIHAI-28697
JCCCUNSPECIFIED
UCLA AIDS InstituteUNSPECIFIED
David Geffen School of Medicine, UCLAUNSPECIFIED
Issue or Number:20
PubMed Central ID:PMC3815450
Record Number:CaltechAUTHORS:20131112-112114444
Persistent URL:https://resolver.caltech.edu/CaltechAUTHORS:20131112-112114444
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:42387
Collection:CaltechAUTHORS
Deposited By: Michelle Trinh
Deposited On:14 Nov 2013 22:00
Last Modified:03 Oct 2019 05:58

Repository Staff Only: item control page